Barinthus Biotherapeutics Statistics

Total Valuation

BRNS has a market cap or net worth of $54.53 million. The enterprise value is -$62.63 million.

Market Cap	54.53M
Enterprise Value	-62.63M

Important Dates

The next estimated earnings date is Thursday, August 8, 2024, before market open.

Earnings Date	Aug 8, 2024
Ex-Dividend Date	n/a

Share Statistics

BRNS has 38.95 million shares outstanding.

Shares Outstanding	38.95M
Owned by Insiders (%)	3.68%
Owned by Institutions (%)	47.66%
Float	27.28M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	163.28
Forward PS	n/a
PB Ratio	0.32
P/FCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 11.15, with a Debt / Equity ratio of 0.07.

Current Ratio	11.15
Quick Ratio	n/a
Debt / Equity	0.07
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-1,831.85

Financial Efficiency

Return on equity (ROE) is -36.70% and return on invested capital (ROIC) is -42.97%.

Return on Equity (ROE)	-36.70%
Return on Assets (ROA)	-31.80%
Return on Capital (ROIC)	-42.97%
Revenue Per Employee	$2,569
Profits Per Employee	-$543,985
Employee Count	130
Asset Turnover	0.00
Inventory Turnover	n/a

Taxes

Income Tax	-2.60M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -36.36% in the last 52 weeks. The beta is -0.51, so BRNS's price volatility has been lower than the market average.

Beta (5Y)	-0.51
52-Week Price Change	-36.36%
50-Day Moving Average	1.81
200-Day Moving Average	2.72
Relative Strength Index (RSI)	36.34
Average Volume (20 Days)	34,590

Short Selling Information

Short Interest	9,148
Short Previous Month	7,210
Short % of Shares Out	0.04%
Short % of Float	n/a
Short Ratio (days to cover)	0.29

Income Statement

In the last 12 months, BRNS had revenue of $334,000 and -$70.72 million in losses. Loss per share was -$1.84.

Revenue	334,000
Gross Profit	334,000
Operating Income	-79.34M
Pretax Income	-73.31M
Net Income	-70.72M
EBITDA	-66.23M
EBIT	-73.27M
Loss Per Share	-$1.84

Full Income Statement

Balance Sheet

The company has $129.97 million in cash and $12.81 million in debt, giving a net cash position of $117.17 million or $3.01 per share.

Cash & Cash Equivalents	129.97M
Total Debt	12.81M
Net Cash	117.17M
Net Cash Per Share	$3.01
Equity (Book Value)	171.83M
Book Value Per Share	4.41
Working Capital	130.30M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$59.57 million and capital expenditures -$3.21 million, giving a free cash flow of -$62.79 million.

Operating Cash Flow	-59.57M
Capital Expenditures	-3.21M
Free Cash Flow	-62.79M
FCF Per Share	-$1.62

Full Cash Flow Statement

Margins

Gross margin is 100.00%, with operating and profit margins of -23,755.69% and -21,173.05%.

Gross Margin	100.00%
Operating Margin	-23,755.69%
Pretax Margin	-21,950.30%
Profit Margin	-21,173.05%
EBITDA Margin	-19,828.74%
EBIT Margin	-21,938.32%
FCF Margin	-18,798.50%

Dividends & Yields

BRNS does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-2.00%
Shareholder Yield	-2.00%
Earnings Yield	-129.68%
FCF Yield	-115.13%

Analyst Forecast

The average price target for BRNS is $5.50, which is 292.86% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$5.50
Price Target Difference	292.86%
Analyst Consensus	Strong Buy
Analyst Count	2
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

BRNS has an Altman Z-Score of -0.58 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-0.58
Piotroski F-Score	2